| Literature DB >> 33920768 |
Przemysław Czeleń1, Beata Szefler1.
Abstract
The glycogen synthase kinase 3β (GSK-3β) is a protein kinase involved in regulating numerous physiological processes such as embryonic development, transcription, insulin action, cell division cycle and multiple neuronal functions. The overexpression of this enzyme is related to many diseases such as schizophrenia, Alzheimer's disease, diabetes and cancer. One of the basic methods of treatment in these cases is the usage of ATP-competitive inhibitors. A significant group of such compounds are indirubin and its analogs, e.g., oxindole derivatives. The compounds considered in this work are 112 newly designed oxindole derivatives. In the first stage, such molecular properties of considered compounds as toxicity and LogP were estimated. The preliminary analysis of the binding capabilities of considered compounds towards the GSK-3β active site was conducted with the use of the docking procedure. Based on obtained molecular properties and docking simulations, a selected group of complexes that were analyzed in the molecular dynamics stage was nominated. The proposed procedure allowed for the identification of compounds such as Oxind_4_9 and Oxind_13_10, which create stable complexes with GSK-3β enzyme and are characterized by the highest values of binding affinity. The key interactions responsible for stabilization of considered ligand-protein complexes were identified, and their dynamic stability was also determined. Comparative analysis including analyzed compounds and reference molecule 3a, which is also an oxindole derivative with a confirmed inhibitory potential towards GSK3B protein, clearly indicates that the proposed compounds exhibit an analogous binding mechanism, and the obtained binding enthalpy values indicate a slightly higher binding potential than the reference molecule.Entities:
Keywords: GSK-3β; docking; inhibition; molecular dynamics; oxindoles
Year: 2021 PMID: 33920768 PMCID: PMC8071161 DOI: 10.3390/biology10040332
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1Characteristic interactions of the oxindole core with amino acids from GSK-3β active site.
Figure 2Oxindole core and functional groups used during creation of ligands.
The values of binding affinity of oxindole monoderivatives towards GSK-3β. Increase in binding affinity estimated relative to the value for Oxind_0_0, equal to −8.4 kcal/mol.
| Name | Binding | Increase in | Name | Binding | Increase in Binding Affinity (%) |
|---|---|---|---|---|---|
| Oxind_11_0 | −10.10 | 20.2 | Oxind_0_9 | −10.44 | 24.3 |
| Oxind_12_0 | −10.00 | 19.0 | Oxind_0_10 | −10.36 | 23.3 |
| Oxind_10_0 | −9.90 | 17.9 | Oxind_0_15 | −10.22 | 21.7 |
| Oxind_9_0 | −9.84 | 17.1 | Oxind_0_14 | −10.20 | 21.4 |
| Oxind_13_0 | −9.80 | 16.7 | Oxind_0_18 | −10.00 | 19.0 |
| Oxind_5_0 | −9.60 | 14.3 | Oxind_0_19 | −9.90 | 17.9 |
| Oxind_20_0 | −9.54 | 13.6 | Oxind_0_5 | −9.80 | 16.7 |
| Oxind_4_0 | −9.40 | 11.9 | Oxind_0_13 | −9.70 | 15.5 |
| Oxind_15_0 | −9.28 | 10.5 | Oxind_0_11 | −9.60 | 14.3 |
| Oxind_14_0 | −9.26 | 10.2 | Oxind_0_12 | −9.58 | 14.0 |
| Oxind_6_0 | −9.20 | 9.5 | Oxind_0_1 | −9.40 | 11.9 |
| Oxind_18_0 | −9.14 | 8.8 | Oxind_0_2 | −9.24 | 10.0 |
| Oxind_1_0 | −9.10 | 8.3 | Oxind_0_4 | −9.20 | 9.5 |
| Oxind_2_0 | −9.00 | 7.1 | Oxind_0_3 | −9.12 | 8.6 |
| Oxind_3_0 | −8.88 | 5.7 | Oxind_0_6 | −9.10 | 8.3 |
| Oxind_8_0 | −8.80 | 4.8 | Oxind_0_8 | −8.90 | 6.0 |
| Oxind_7_0 | −8.50 | 1.2 | Oxind_0_7 | −8.80 | 4.8 |
| Oxind_17_0 | −8.30 | −1.2 | Oxind_0_16 | −8.60 | 2.4 |
| Oxind_19_0 | −8.16 | −2.9 | Oxind_0_17 | −8.30 | −1.2 |
| Oxind_16_0 | −8.00 | −4.8 | Oxind_0_20 | −8.24 | −1.9 |
The values of binding affinity and molecular parameters for the structures exhibiting the best properties. IC/IC ref represents normalized factors describing the decrease in inhibition constant relative to the reference system (IC ref = 696.17 nM).
| Name | LogP | Toxicity | Binding Affinity | Increase in | Inhibition Constant (nM) | IC/IC Ref | |
|---|---|---|---|---|---|---|---|
| 1. | Oxind_13_10 | 2.38 | 0.28 | −11.60 | 38.10 | 3.14 | 221.6 |
| 2. | Oxind_12_15 | 3.07 | 0.38 | −11.50 | 36.90 | 3.72 | 187.2 |
| 3. | Oxind_9_10 | 5.12 | 0.39 | −11.46 | 36.43 | 3.98 | 175.0 |
| 4. | Oxind_4_9 | 3.58 | 0.32 | −11.40 | 35.71 | 4.40 | 158.1 |
| 5. | Oxind_5_9 | 2.68 | 0.39 | −11.22 | 33.57 | 5.97 | 116.7 |
| 6. | Oxind_9_15 | 3.64 | 0.19 | −11.20 | 33.33 | 6.17 | 112.8 |
| 7. | Oxind_4_10 | 2.04 | 0.07 | −11.14 | 32.62 | 6.83 | 102.0 |
| 8. | Oxind_15_9 | 2.58 | 0.25 | −11.12 | 32.38 | 7.06 | 98.6 |
| 9. | Oxind_12_14 | 2.99 | 0.1 | −11.10 | 32.14 | 7.30 | 95.3 |
| 10. | Oxind_10_14 | 1.82 | 0.04 | −11.02 | 31.19 | 8.36 | 83.3 |
| 11. | Oxind_4_18 | 1.67 | 0.29 | −10.96 | 30.48 | 9.25 | 75.2 |
| 12. | Oxind_20_15 | 2.18 | 0.19 | −10.90 | 29.76 | 10.24 | 68.0 |
| 13. | Oxind_10_13 | 3.38 | 0.28 | −10.90 | 29.76 | 10.24 | 68.0 |
| 14. | Oxind_10_18 | 3.43 | 0.03 | −10.88 | 29.52 | 10.59 | 65.7 |
| 15. | Oxind_12_18 | 3.48 | 0.18 | −10.88 | 29.52 | 10.59 | 65.7 |
Figure 3The graphic representations of interactions of oxindole derivatives with the GSK-3β active site identified during the docking stage. The markings on the left side of individual figures are the names of ligands forming complexes with the active site.
The average values of RMSD for ligands and enzymes for all steps used during structural analysis. The values in italics represent standard deviations (SDs). The LIG captions represent values characterizing appropriate ligand molecules in considered complexes.
| Oxind_4_9 | Oxind_5_9 | Oxind_9_10 | Oxind_12_15 | Oxind_13_10 | 3a | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK3β | LIG | GSK3β | LIG | GSK3β | LIG | GSK3β | LIG | GSK3β | LIG | GSK3β | LIG | |
|
| 2.47 | 1.24 | 2.42 | 1.62 | 2.28 | 0.77 | 2.61 | 1.97 | 2.25 | 0.50 | 2.37 | 1.14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure 4Distributions presenting mutual dependencies between values of angles and lengths characterizing hydrogen bonds created by Oxind_4_9 and Oxind_13_10 molecules with chosen amino acids from the GSK-3β active site. The headings of the individual columns define the name of the ligand, while the line descriptions define the hydrogen bond under consideration.
Distribution of the most frequently created hydrogen bonds between ligand molecules and selected amino acids from the GSK-3β active site. The hydrogen bonds in the table represent middle values of intervals with a width of 0.2 Å.
| Hydrogen Bond | Population% | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ∑ | 1.6 Å | 1.8 Å | 2.0 Å | 2.2 Å | 2.4 Å | 2.6 Å | 2.8 Å | 3.0 Å | |
| Oxind_4_9 | |||||||||
| Ligand ( |
| 1.8 | 39.4 | 44.2 | 12.4 | 2.0 | 0.2 | 0.1 | 0,0 |
| Ligand( |
| 0.3 | 19.9 | 48.0 | 22.9 | 6.4 | 1.9 | 0.5 | 0.1 |
| Ligand ( |
| 2.7 | 43.7 | 37.1 | 10.7 | 3.4 | 1.0 | 0.4 | 0.2 |
| Ligand ( |
| 0.0 | 0.3 | 1.2 | 3.5 | 6.8 | 10.2 | 14.0 | 14.0 |
| Ligand ( |
| 0.1 | 1.7 | 2.4 | 1.0 | 0.4 | 0.2 | 0.5 | 1.1 |
| Ligand ( |
| 0.8 | 26.0 | 36.2 | 16.2 | 6.0 | 2.9 | 1.4 | 0.9 |
| Oxind_5_9 | |||||||||
| Ligand ( |
| 1.6 | 48.1 | 40.2 | 8.6 | 1.1 | 0.3 | 0.1 | 0.0 |
| Ligand( |
| 0.2 | 21.5 | 44.2 | 23.4 | 7.2 | 2.1 | 0.9 | 0.1 |
| Ligand ( |
| 2.4 | 41.5 | 34.5 | 10.6 | 3.2 | 1.4 | 0.8 | 0.6 |
| Ligand ( |
| 0.2 | 6.2 | 12.2 | 6.4 | 4.1 | 1.7 | 1.5 | 1.5 |
| Ligand ( |
| 0.1 | 2.4 | 5.6 | 4.9 | 3.3 | 2.9 | 2.4 | 3.4 |
| Oxind_9_10 | |||||||||
| Ligand ( |
| 1.4 | 34.1 | 46.0 | 14.4 | 3.4 | 0.6 | 0.0 | 0.1 |
| Ligand( |
| 0.3 | 26.6 | 48.7 | 19.3 | 4.3 | 0.7 | 0.0 | 0.1 |
| Ligand ( |
| 4.2 | 49.7 | 34.7 | 7.3 | 2.4 | 0.6 | 0.2 | 0.2 |
| Ligand ( |
| 0.0 | 0.0 | 0.9 | 3.3 | 6.4 | 11.4 | 11.4 | 12.1 |
| Ligand ( |
| 1.6 | 10.6 | 18.6 | 16.2 | 13.5 | 8.5 | 6.3 | 4.6 |
| Oxind_12_15 | |||||||||
| Ligand ( |
| 0.1 | 21.7 | 41.9 | 20.4 | 7.4 | 2.7 | 0.8 | 0.7 |
| Ligand( |
| 0.8 | 25.3 | 42.9 | 21.4 | 5.1 | 1.7 | 0.5 | 0.8 |
| Ligand ( |
| 0.3 | 13.0 | 15.9 | 7.8 | 3.1 | 1.9 | 1.3 | 0.7 |
| Ligand ( |
| 0.0 | 2.9 | 13.0 | 11.8 | 7.8 | 6.4 | 4.1 | 5.1 |
| Oxind_13_10 | |||||||||
| Ligand ( |
| 0.6 | 29.2 | 48.6 | 18.1 | 2.6 | 0.8 | 0.2 | 0.0 |
| Ligand( |
| 0.6 | 34.2 | 49.5 | 13.3 | 2.2 | 0.2 | 0.0 | 0.0 |
| Ligand ( |
| 3.8 | 46.5 | 31.6 | 8.1 | 2.9 | 0.5 | 0.2 | 0.3 |
| Ligand ( |
| 6.3 | 24.4 | 21.9 | 11.5 | 6.4 | 4.0 | 2.9 | 2.9 |
| Ligand ( |
| 0.0 | 0.7 | 1.7 | 3.5 | 5.6 | 7.6 | 13.7 | 17.4 |
| 3a | |||||||||
| Ligand ( |
| 2.5 | 55.6 | 36.0 | 5.1 | 0.9 | 0.0 | 0.0 | 0.0 |
| Ligand( |
| 0.5 | 18.2 | 35.9 | 22.1 | 10.3 | 4.1 | 2.7 | 2.7 |
Figure 5The distributions of distances measured between hydrophobic moieties of particular residues from GSK-3β active site and carbon atoms from ligand molecules. The grey distributions represent residues interacting with the molecular core, the blue distributions represent residues interacting with functional groups localized in the R1 position and the orange distributions represent residues interacting with functional groups connected to the R2 position. The markings on the left side of individual figures are the names of ligands involved in interactions presented on particular charts.
The values of binding enthalpy ΔH (kcal/mol) estimated for GSK-3β complexes considered during the molecular dynamics stage (EVDWAALS = van der Waals contribution from MM; EEL = electrostatic energy; EPB = the electrostatic contribution to the solvation free energy calculated by PB; ECAVITY = nonpolar contribution to the solvation free energy; ΔH = final estimated binding enthalpy).
| Oxind_4_9 | Oxind_5_9 | Oxind_9_10 | Oxind_12_15 | Oxind_13_10 | 3a | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ΔE | SD | ΔE | SD | ΔE | SD | ΔE | SD | ΔE | SD | ΔE | SD | |
|
| −48.31 | 2.63 | −45.52 | 3.21 | −50.63 | 3.79 | −46.56 | 6.62 | −49.80 | 2.98 | −47.91 | 2.76 |
|
| −51.29 | 3.88 | −49.62 | 4.95 | −49.80 | 5.20 | −47.52 | 7.38 | −50.85 | 3.66 | −49.84 | 3.67 |
|
| 65.76 | 4.94 | 67.84 | 6.89 | 70.68 | 5.97 | 68.54 | 9.50 | 66.19 | 4.38 | 65.21 | 4.15 |
|
| −3.97 | 1.15 | −4.29 | 1.66 | −3.95 | 1.96 | −3.58 | 1.99 | −4.17 | 1.59 | −3.85 | 1.35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|